Hemogenyx Pharmaceuticals Plc (HEMO.L)

GBp 320.0

(-8.57%)

Market Cap (In GBp)

11.21 Million

Revenue (In GBp)

-

Net Income (In GBp)

-6.69 Million

Avg. Volume

4.58 Million

Currency
GBp
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
270.0-2853.6
PE
-
EPS
-
Beta Value
3.256
ISIN
GB00BYX3WZ24
CUSIP
G4R59S104
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Vladislav Sandler Ph.D.
Employee Count
-
Website
https://www.hemogenyx.com
Ipo Date
2015-11-09
Details
Hemogenyx Pharmaceuticals Plc, a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood diseases. It is involved in developing products for bone marrow/hematopoietic stem cell (BM/HSC) transplant market, including CDX bi-specific antibody targeting relapsed/refractory acute myeloid leukaemia (R/R AML), subset of acute lymphoblastic leukaemia, and myelodysplastic syndrome conditioning bone marrow transplants to substitute traditional chemotherapy and/or radiation; HEMO-CAR-T therapy, a chimeric antigen receptor T-cells to identify and destroy human AML-derived cells in vitro and in vivo; and Human Postnatal Hematopoietic Endothelial Cells, a stem cell therapy product for BM/HSC transplants. The company was founded in 2012 and is headquartered in London, the United Kingdom.